Surveillance of adverse events following vaccination in the French armed forces, 2011-2012

Public Health

Volumn 129, Issue 6, 2015, Pages 763-768

  Mayet, A ^a   Duron, S ^a   Meynard, J B ^a,b   Koeck, J L ^c   Deparis, X ^a,b   Migliani, R ^a,b  

^a Epidemiologic and Public Health Military Center   (France)

^b Ecole du Val de Grace   (France)

^c Medical Biology Service   (France)

Author keywords

Armed forces; Vaccine; Vaccine adverse event

Indexed keywords

BCG VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; DIPHTHERIA POLIOMYELITIS TETANUS VACCINE; HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; RECOMBINANT HEPATITIS B VACCINE; TYPHOID VACCINE; VACCINE; YELLOW FEVER VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DTPP VACCINE; POLIOMYELITIS VACCINE;

ARMED FORCES; DISEASE INCIDENCE; HEALTH AND SAFETY; HEALTH SERVICES; TOLERANCE; VACCINATION; VACCINE;

ABSENTEEISM; ADULT; ANAPHYLACTOID PURPURA; ARMY; ARTHRALGIA; ARTICLE; ASTHENIA; ASTHMA; DISEASE SEVERITY; DISEASE SURVEILLANCE; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; FACIAL NERVE PARALYSIS; FAINTNESS; FEMALE; FEVER; FRENCHMAN; GASTROINTESTINAL SYMPTOM; GUILLAIN BARRE SYNDROME; HEADACHE; HUMAN; HYPESTHESIA; INCIDENCE; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; LYMPHADENITIS; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MENINX DISORDER; MIDDLE AGED; MILITARY SERVICE; MYALGIA; OPTIC NEURITIS; PARESTHESIA; PRACTICE GUIDELINE; TINNITUS; UNSPECIFIED SIDE EFFECT; URTICARIA; YOUNG ADULT; DRUG SURVEILLANCE PROGRAM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FRANCE; IMMUNIZATION; POSTMARKETING SURVEILLANCE; SOLDIER; STATISTICS AND NUMERICAL DATA;

FRANCE;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; BCG VACCINE; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FRANCE; HUMANS; IMMUNIZATION SCHEDULE; MALE; MENINGOCOCCAL VACCINES; MIDDLE AGED; MILITARY PERSONNEL; POLIOVIRUS VACCINE, INACTIVATED; PRODUCT SURVEILLANCE, POSTMARKETING; VACCINES; VACCINES, COMBINED; VACCINES, CONJUGATE; YOUNG ADULT;

EID: 84931563265     PISSN: 00333506     EISSN: 14765616     Source Type: Journal    
DOI: 10.1016/j.puhe.2015.03.003     Document Type: Article

References (20)

1. Mayet A., Haus-Cheymol R., Bouaiti E.A., Decam C., Simon F., Mérens A., et al. Adverse events following vaccination in the french armed forces: an overview of surveillance conducted from 2002 to 2010. Euro Surveill 2012, 17. pii:20193.
2. Zhou W., Pool V., Iskander J.K., English-Bullard R., Ball R., Wise R.P., et al. Surveillance for safety after immunization: VAE reporting system (VAERS) - United States, 1991-2001. MMWR Surveill Summ 2003, 52:1-24.
3. Khromava A.Y., Eidex R.B., Weld L.H., Kohl K.S., Bradshaw R.D., Chen R.T., et al. Yellow Fever Vaccine Safety Working Group. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 2005, 23:3256-3263.
4. Mayet A., Génicon C., Duron S., Haus-Cheymol R., Ficko C., Bédubourg G., et al. The measles outbreak in the French military forces - 2010-2011: results of epidemiological surveillance. J Infect 2013, 66:271-277.
5. Génicon C., Meynard J.B., Duron S., Haus-Cheymol R., Ollivier L., Le Goff C., et al. Feedback on the management of the 2011 measles outbreak by French military general practitioners: an evaluation study. Rev Épidémiol Santé Publ 2014, 62:119-126.
6. Begaud B., Chaslerie A., Haramburu F. Organization and results of drug vigilance in France. Rev Épidémiol Sante Publ 1994, 42:416-423. [in French].
7. Mayet A., Ligier C., Gache K., Manet G., Nivoix P., Dia A., et al. Adverse events following pandemic influenza vaccine Pandemrix® reported in the French military forces - 2009-2010. Vaccine 2011, 29:2576-2581.
8. Weber J.C.P. Epidemiology of adverse reactions to nonsteroidal anti-inflammatory drugs. Advances in inflammation research 1984, vol. 6:1-7. Raven Press, New York.
9. Talbot E.A., Brown K.H., Kirkland K.B., Baughman A.L., Halperin S.A., Broder K.R. The safety of immunizing with tetanus-diphtheria-acellular pertussis vaccine (Tdap) less than 2 years following previous tetanus vaccination: experience during a mass vaccination campaign of healthcare personnel during a respiratory illness outbreak. Vaccine 2010, 28:8001-8007.
10. Yih W.K., Nordin J.D., Kulldorff M., Lewis E., Lieu T.A., Shi P., et al. An assessment of the safety of adolescent and adult tetanus-diphtheria-acellular pertussis (Tdap) vaccine, using active surveillance for adverse events in the Vaccine Safety Datalink. Vaccine 2009, 27:4257-4262.
11. Sicard S., Berger F., Migliani R., Deparis X., Michel R., Mayet A. An approach for assessing effectiveness of a vaccination campaign against pertussis among young adults: the example of the French armed forces. J Infect 2007-2012, 2014(68):395-397.
12. Haut conseil de la santé publique. Avis relatif à l'utilisation du vaccin méningococcique tétravalent conjugué A, C, Y, W135 NIMENRIX® et à la place respective des vaccins méningococciques tétravalents conjugués et non conjugués. https://www.mesvaccins.net/textes/hcspa20120712_meningonimenrix.pdf.
13. Pace D., Pollard A.J., Messonier N.E. Quadrivalent meningococcal conjugate vaccines. Vaccine 2009, 27(Suppl.):B30-B41.
14. Vesikari T., Karvonen A., Bianco V., Van der Wielen M., Miller J. Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second part of life: an open, randomized controlled trial. Vaccine 2011, 29:4274-4284.
15. de la Rocque F., Cohen R., Vie le Sage F., Bocquet A., Boucherat M., Levy Bruhl D. French paediatrician and general practitionner's survey about actual and future BCG use. Arch Pediatr 2005, 12:1665-1669. [in French].
16. Wattrelot P., Brion J.P., Labarère J., Billette de Villemeur A., Girard-Blanc M.F., Stahl J.P. Vaccination practices following the end of BCG compulsory vaccination. A cross sectional survey of general practitioners and pediatricians. Arch Pediatr 2010, 17:118-124. [in French].
17. Hughes R.A., Cornblath D.R. Guillain-Barré syndrome. Lancet 2005, 366:1653-1666.
18. Vucic S., Kiernan D.E.R., Cornblath D.R. Guillain-Barré syndrome: an update. J Clin Neurosci 2009, 16:733-741.
19. Black S., Eskola J., Siegrist C.-A., Halsey N., MacDonald N., Law B., et al. Importance of background rates of disease in assessment of vaccine safety during mass immunization with pandemic H1N1 influenza vaccines. Lancet 2010, 374:2115-2122.
20. Black S., Block S.L. Use of MenACWY-CRM in adolescents in the United States. J Adolesc Health 2013, 52:271-277.